Therefore, a new strategy to delay or prevent disease progression in PBC patients with an incomplete response to UDCA is urgently required. Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic progenitor cells capable of differentiating into multiple lineages.[10-13] MSCs have been used as a therapeutic strategy for tissue regeneration and repair, and their potential immunomodulatory capacity has also raised significant clinical interest.[14-17] Although these properties are not completely understood, emerging evidence from animal and human studies makes MSCs a promising

therapeutic tool for autoimmune disease. The umbilical cord-derived MSC (UC-MSC) is of particular Talazoparib datasheet interest because of its relatively easy accessibility and abundant source,[18] making it a good substitute for MSC in future clinical Z-IETD-FMK cost studies. Recently, transfusion of UC-MSCs has been reported to significantly improve symptoms in patients with severe autoimmune diseases, such as severe and refractory systemic lupus erythematosus,[19] therapy-resistant rheumatoid arthritis,[20] and immune thrombocytopenia patients,[21] with few adverse effects. Recently, our

own 上海皓元医药股份有限公司 research has indicated that UC-MSC therapy is well tolerated and has the potential to

improve liver function, and reduce ascites and mortality in hepatitis B virus-associated patients with decompensated liver cirrhosis[22] and liver failure,[23] respectively. The goal of the present pilot study was to evaluate the safety and initial efficacy of UC-MSC transplantation in PBC patients with an incomplete response to UDCA therapy. Seven PBC patients with an incomplete response to UDCA were enrolled in the study between May 6, 2010 and March 5, 2011 in Research Center for Biological Therapy/Beijing 302 Hospital. These patients (ages between 33 and 58 years) were diagnosed with PBC based on the presence of an antimitochondrial antibody (AMA) titer > 1 : 40, and serum alkaline phosphatase (ALP) at least twice the upper limit of normal in the absence of biliary obstruction, which was in accordance with the American Association for the Study of Liver Diseases practice guidelines.[1] Additionally, enrolled patients did not have a normalization of their ALP after a minimum of six months of treatment with adequate doses of UDCA.[8, 24, 25] The exclusion criteria were as follows: pregnancy; coexisting liver disease (hepatitis A, hepatitis B, and hepatitis C, etc.